The advancement of high-dose chemotherapy and dose intensification schedules

Annals of Oncology

Volumn 8, Issue SUPPL. 3, 1997, Pages

  Leonard, R C F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adjuvant therapy; Breast cancer; High dose chemotherapy; Metastases

Indexed keywords

FLUOROURACIL; PACLITAXEL DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DOSE CALCULATION; DRUG MEGADOSE; EARLY DIAGNOSIS; FEMALE; HISTORY OF MEDICINE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030823878     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_3.S3     Document Type: Conference Paper

References (32)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: Lippincott 1993; 1264-332.
2. Muer CS, Boile P. The burden of cancer in Europe. Eur J Cancer 1990; 26: 1111-3.
3. Vahdal L, Antman K. High-dose therapy for breast cancer. Blood Rev 1995; 9: 191-200.
4. Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med 1996; 125: 599-604.
5. Nemoto T, Vana J, Bedwani RN et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917-24.
6. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
7. Davidson NE, Abeloff MD. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. J Natl Cancer Inst 1992; 84: 301-5.
8. Jones SE, Moon TE, Bonadonna G et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10: 387-95.
9. Roman-Unfer S, Bitran JD. High-dose chemotherapy for malignancies: A review. Compr Ther 1996; 22(2): 107-20.
10. McCauley DL. High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. Am J Health Syst Pharm 1996; 53: 521-34.
11. Thornton HM. Breast cancer trials: A patient's viewpoint. Lancet 1992; 339(8784): 44-5.
12. Liberatti A. NHS Guidelines on Breast Cancer - the Evidence. London: Department of Health and Social Security: July 1996.
13. Williams SF, Mick R, Desser R et al. High dose consolidative therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-30.
14. Kaminer L, Williams S, Beschorner J et al. High dose chemotherapy with autologous stem cell support in the treatment of stage IV breast carcinoma. Proc Am Soc Clin Oncol 1989; 8: 45-8.
15. Williams SF, Gilewski T, Mick R et al. High dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 1992; 10: 1743-7.
16. Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102-10.
17. Antman K. Dose intensive treatment in breast cancer. In Armitage J. Antman K (eds): High Dose Cancer Treatment. Baltimore: Williams and Wilkins 1992; 702-18.
18. Peters WB, Shpall EJ, Jones RB et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
19. Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the impact of selection processes for high-dose chemotherapy (HDCT) on the outcome of patients (PT) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995; 14: 95 (Abstr 78).
20. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with haemopoietic rescue as primary treatment for metastatic breast cancer: A randomised trial. J Clin Oncol 1995; 13: 2483-9.
21. Peters WB, Jones RB, Vredenburgh JJ et al. A large, prospective randomised trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1995; 14: 121 (Abstr 149).
22. Holland HK, DIXSP, Gellel RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa and carboplatin plus autologous marrow/stem cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14(4): 1156-64.
23. Jones RB, Shpall EJ, Ross M et al. AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support for advanced breast cancer. Current results. Proc Am Soc Clin Oncol 1990; 9: 9 (Abstr).
24. Kennedy MJ, Beveridge RA, Rowley SD et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-6.
25. Mulder NH, Mulder PO, Sleijfer DT et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer 1993; 29A: 668-71.
26. Dunphy FR, Spitzer G. Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 1992; 84: 128-9.
27. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 1994; 12: 37-44.
28. Dunphy FR, Spitzer G, Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-67.
29. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-9.
30. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
31. Jones A, Smith I, O'Brien M et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic or locally advanced breast cancer. J Clin Oncol 1994; 12: 1693-8.
32. Gabra H, Cameron D, Mackay J, Leonard RCF. Phase I/II study of continuous infusion fluorouracil and bolus adriamycin (AcF) for advanced breast cancer. Br J Cancer 1997 (in press).